Evidence map›Paper›PMID 32556851›Full record

ReviewCardiovascular drugs and therapy2021

Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.

Roy O Mathew, Robert S Rosenson, Radmila Lyubarova, Rafia Chaudhry, Salvatore P Costa, Sripal Bangalore, Mandeep S Sidhu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Roy O Mathew *Columbia V.A. Health Care System, 6439 Garners Ferry Road, Columbia, SC, 29209, USA. roy.mathew@va.gov.ORCID http://orcid.org/0000-0002-5582-3165
Robert S Rosenson *Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Radmila LyubarovaAlbany Medical College and Albany Medical Center, Albany, NY, USA.
Rafia ChaudhryUniversity of California, San Francisco, CA, USA.
Salvatore P CostaGeisel School of Medicine at Dartmouth, Hanover, NH, USA.
Sripal BangaloreNew York University School of Medicine, New York, NY, USA.
Mandeep S SidhuAlbany Medical College and Albany Medical Center, Albany, NY, USA.
Albany Medical Center Hospital · USDartmouth College · USIcahn School of Medicine at Mount Sinai · USNew York University · USUniversity of California, San Francisco · USUniversity of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Among patients with CKD, not yet on dialysis, there is clinical trial evidence for the use of statins with or without ezetimibe to reduce ASCVD events. Newer cholesterol lowering agents have been introduced for the management of hyperlipidemia to reduce ASCVD, but these therapies have not been tested in the CKD population except in secondary analyses of patients with primarily CKD stage 3. This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population.

Indexed as

AtherosclerosisEzetimibeFibric AcidsGlomerular Filtration RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasHypolipidemic AgentsLipidsNiacinPatient AcuityPCSK9 InhibitorsPractice Guidelines as TopicProprotein Convertase 9Randomized Controlled Trials as TopicRenal DialysisEzetimibeFibric AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipidsNiacinPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Atherosclerotic cardiovascular diseaseChronic kidney diseaseDyslipidemiaEnd-stage renal diseasePCSK9 inhibitors

Identifiers

PMID32556851
OpenAlexW3036469973

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.